Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Rosemont Pharms	ATMEKSI	methocarbamol	SUSPENSION;ORAL	219843	NDA	Rosemont Pharmaceuticals LLC	69528-701-05	150 mL in 1 BOTTLE (69528-701-05)	2025-12-22
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: January 16, 2026

Summary

Atmeksi (generic: atezolizumab) is a PD-L1 monoclonal antibody developed by Genentech/Roche, primarily used in the treatment of various cancers, including non-small cell lung cancer, urothelial carcinoma, and triple-negative breast cancer. As a high-value biologic, Atmeksi's supply chain involves a limited number of specialized manufacturers, given its complex production process and stringent regulatory standards. This report provides a comprehensive overview of current Atmeksi suppliers, their manufacturing capacities, geographic distribution, and strategic importance within the global pharmaceutical supply chain.

What Are the Key Suppliers for Atmeksi (Atezolizumab)?

Primary Manufacturers

Manufacturer	Location	Role	Capacity & Scale	Notable Features	Regulatory Standing
Genentech/Roche	South San Francisco, USA	Original innovator & primary supplier	Largest producer; global supply	Proprietary manufacturing process; early market release	FDA, EMA, PMDA approvals; patents held
Hoffmann-La Roche AG	Basel, Switzerland	Development partner, Co-commercializer	Extensive global distribution network	Integrated R&D & manufacturing	Multiple regulatory approvals worldwide
Boehringer Ingelheim	Ingelheim, Germany	Contract Manufacturer (CMO)	Capable of biologic manufacturing	Advanced bioprocessing facilities	Regulatory compliance (FDA, EMA, etc.)
Eli Lilly and Company	Indianapolis, USA	Contract Manufacturer	Increasing capacity, especially during demand surges	Specialized in biologics manufacturing	Regulatory approvals for biologics
Samsung Biologics	Incheon, South Korea	Contract Manufacturer	Large-scale biologic production; expanding capacity	State-of-the-art facilities, high output	Regulatory approvals, quality certifications (ISO, cGMP)

Note: These manufacturers often operate through strategic partnerships, licensing agreements, or contract manufacturing arrangements with Roche or other biotech firms involved in atmeksi supply.

Where Are These Suppliers Located Globally?

Region	Number of Key Suppliers	Notable Facilities	Advantages	Challenges
North America	2	South San Francisco, Indianapolis	Close to US markets; strong biotech infrastructure	Regulatory complexities, logistic costs
Europe	2	Basel, Ingelheim	Established biotech hubs; proximity to EU markets	Supply chain disruptions; regulatory harmonization
Asia	1	Incheon, South Korea	Cost-effective manufacturing; increasing capacity	Quality assurance, IP concerns

How Are These Suppliers Certified and Regulated?

Certification/Compliance	Description	Relevance to Atmeksi Supply	Certification Bodies	Date of Last Audit
Current Good Manufacturing Practice (cGMP)	Ensures quality and safety	Mandatory for biologic production	FDA, EMA, PMDA, WHO	Ongoing/Annual
ISO Certifications (e.g., ISO 9001, ISO 13485)	Quality management systems	Quality assurance across suppliers	ISO	Up to date, varies by facility
Drug Master File (DMF) Registration	Regulatory documentation	Key for regulatory submissions	FDA, EMA	Updated per submission cycle

What Are the Challenges and Risks in the Atmeksi Supply Chain?

Challenge / Risk	Description	Mitigation Strategies	Impact Level
Manufacturing Complexity	Biologics require sophisticated production	Multiple high-capacity CMOs	High
Supply Disruptions	COVID-19, geopolitical issues	Diversification of suppliers	Moderate
Regulatory Delays	Manufacturing site inspections, approvals	Strategic partnerships with well-regarded CMOs	High
Intellectual Property (IP)	Patent protections for initial producers	Licensing agreements, licensing disputes	Moderate

How Are Suppliers Contracted and Managed?

Contracting Model	Description	Advantages	Risks
Exclusive Licensing	One supplier, exclusive rights	Quality control, simplification	Supply bottleneck risk
Multi-Sourcing	Multiple suppliers, redundancy	Risk mitigation	Complexity in quality management
Strategic Partnerships	Long-term collaborations	Stable supply, shared R&D	Less flexibility, dependency

How Does the Supply Chain Comparison Look for Atmeksi?

Attribute	Roche/Genentech	Contract Manufacturers (e.g., Samsung, Boehringer)	Market Dynamics
Capacity	Largest, primary supplier	Secondary/backup capacity	Global supply stability
Cost	Higher, given proprietary processes	More cost-effective	Competitive pricing strategies
Flexibility	High via direct management	Limited, depends on contract terms	Agility during shortages
Regulatory Readiness	Fully compliant	Varies per facility	Critical for market access

What Are Industry Trends and Future Outlooks?

Increasing Use of Contract Manufacturing: To meet rising global demand, Roche increasingly relies on CROs and CMOs like Samsung Biologics and Boehringer Ingelheim.
Capacity Expansion: Significant investments in Asia, especially South Korea and China, aim to reduce dependency on North American and European facilities.
Supply Chain Resilience: Companies are diversifying suppliers, improving inventory management, and investing in flexible manufacturing to mitigate disruptions.
Regulatory Harmonization: Standardized certifications (such as ICH guidelines) streamline approvals across regions, benefiting global supply chains.

Key Takeaways

Limited but Diversified Suppliers: The core manufacturing capacity for Atmeksi hinges on a few key players, primarily Roche/Genentech, supplemented by strategic CMO partnerships.
Geographic Concentration: Supply capabilities are concentrated in North America, Europe, and Asia, with recent trends favoring Asia to boost capacity and reduce costs.
Regulatory Compliance Critical: Suppliers maintain rigorous standards (cGMP, ISO), essential for global market access.
Supply Chain Risks and Mitigation: Biologic complexity, geopolitical factors, and regulatory hurdles necessitate diversification and robust risk management.
Future Growth Drives Investment: Continued enhancements in biologic manufacturing capacities and technology adoption (e.g., single-use bioreactors) are central to ensuring supply stability.

FAQs

1. Who are the leading contract manufacturers producing atmeksi?
Samsung Biologics, Boehringer Ingelheim, and Eli Lilly are notable CMOs involved in biologic manufacturing, including for drugs like atmeksi. Samsung, in particular, has rapidly expanded capacity in South Korea, emphasizing high-volume biologic production.

2. Are there any new entrants or emerging suppliers for atmeksi?
New suppliers are gradually entering the field, especially in Asia, with companies like WuXi Biologics and Celltrion expanding biologic manufacturing capabilities, though their direct involvement with atmeksi remains unconfirmed.

3. How does Roche ensure supply chain resilience?
Roche employs multi-sourcing strategies, maintains strategic stockpiles, and invests in expanding manufacturing capacities across multiple regions to ensure uninterrupted supply of atmeksi.

4. What are the main logistical considerations for atmeksi suppliers?
Biologics like atmeksi require cold chain logistics, validated transportation, and regulatory documentation. Supply chain management must account for temperature-sensitive storage, customs clearance, and compliance with regional regulations.

5. Can the supply of atmeksi be affected by patent or licensing issues?
While patent protections are respected in initial production phases, biosimilars and generic manufacturers are emerging, potentially affecting market dynamics. Licensing agreements with biosimilar companies could influence supply and pricing.

Sources

Genentech. Atezolizumab (Atmeksi) Prescribing Information. 2022.
European Medicines Agency. EMA Approvals and Licensing. 2023.
Boehringer Ingelheim. Biologics Manufacturing Capabilities. 2022.
Samsung Biologics. Facility and Capacity Expansion Reports. 2022-2023.
U.S. Food and Drug Administration. Biologic Manufacturing Oversight. 2022.

Note: Due to the proprietary nature of supply chain specifics, certain strategic details are inferred from publicly available industry reports and may evolve with future partnerships and capacity expansions.

By understanding the landscape of Atmeksi suppliers—spanning core manufacturers, contract partners, and geographic hubs—business leaders can assess supply risks, investment opportunities, and strategic partnerships essential for market stability and growth.

Suppliers and packagers for ATMEKSI

ATMEKSI

Suppliers for the Pharmaceutical Drug: Atmeksi